Teva Pharmaceutical Industries Limited Company Profile
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 38.61 -1.40%
Teva Pharmaceutical Industries at a glance
Teva Pharmaceutical Industries Limited (NYSE: TEVA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Tel Aviv-Yafo, Israel. Teva Pharmaceutical Industries is led by Mr. Richard D. Francis and employs about 31,173 people. At a market capitalization of $45.60 billion, it is considered a large-cap company.
Its SEC Central Index Key (CIK) is 0000818686, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Teva Pharmaceutical Industries do?
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Business description based on the company's public filings.
Company information
- Legal name
- Teva Pharmaceutical Industries Limited
- Ticker
- NYSE: TEVA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard D. Francis
- Employees
- 31,173
- Headquarters
- 124 Dvora HaNevi’a St., Tel Aviv-Yafo, Israel
- Phone
- 972 3 914 8213
- Website
- tevapharm.com
- Market cap
- $45.60B
- SEC CIK
- 0000818686
- Latest annual report
- 10-K · Feb 3, 2026
Companies similar to Teva Pharmaceutical Industries
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ONCBeOne Medicines Ltd. ADR | 364.02 | +0.34% | $41.41B | vs TEVA |
| RPRXRoyalty Pharma plc Class A | 56.76 | +0.57% | $32.80B | vs TEVA |
| TAKTakeda Pharmaceutical Company Limited ADR | 18.37 | +1.49% | $58.68B | vs TEVA |
| ALNYAlnylam Pharmaceuticals Inc. | 224.41 | +0.21% | $30.03B | vs TEVA |
| ZTSZoetis Inc. Class A | 71.55 | +0.31% | $29.57B | vs TEVA |
| ROIVRoivant Sciences Ltd. | 34.75 | -2.20% | $25.10B | vs TEVA |
| UTHRUnited Therapeutics Corporation | 545.00 | +0.62% | $23.38B | vs TEVA |
| GMABGenmab A/S ADS | 36.65 | -3.04% | $22.54B | vs TEVA |